{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT06128551","nct_id":"NCT06128551","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06128551. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Phase 2 only","label":"Elironrasib Monotherapy","type":"EXPERIMENTAL"},{"description":"Phase 2 only","label":"Daraxonrasib Monotherapy","type":"EXPERIMENTAL"},{"description":"Phase 1b and 2","label":"Daraxonrasib + Elironrasib Combination","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-06","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer (NSCLC)","Colorectal Cancer","Pancreatic Ductal Adenocarcinoma"],"enrollment":{"count":534,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Elironrasib","otherNames":["RMC-6291"],"type":"DRUG"},{"name":"Daraxonrasib","otherNames":["RMC-6236"],"type":"DRUG"}],"last_update":"2026-09-22","lead_sponsor":"Revolution Medicines, Inc.","official_title":"Phase 1b/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients With Advanced KRAS G12C-Mutated Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2028-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of patients with adverse events (AEs) in Phase 1b","timeFrame":"Up to approximately 3 years"},{"measure":"Changes in vital signs in Phase 1b","timeFrame":"Up to approximately 3 years"},{"measure":"Changes in clinical laboratory test values in Phase 1b","timeFrame":"Up to approximately 3 years"},{"measure":"Dose Limiting Toxicities in Phase 1b","timeFrame":"21 days"},{"measure":"Changes in ECGs in Phase 1b","timeFrame":"Up to approximately 3 years"},{"measure":"Overall Response Rate (ORR) in Phase 2","timeFrame":"Up to approximately 3 years"}],"references":[{"citation":"Cregg J, Edwards AV, Chang S, Lee BJ, Knox JE, Tomlinson ACA, Marquez A, Liu Y, Freilich R, Aay N, Wang Y, Jiang L, Jiang J, Wang Z, Flagella M, Wildes D, Smith JAM, Singh M, Wang Z, Gill AL, Koltun ES. Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. J Med Chem. 2025 Mar 27;68(6):6064-6083. doi: 10.1021/acs.jmedchem.4c02314. Epub 2025 Mar 8.","pmid":"40056080","type":"DERIVED"}],"start_date":{"date":"2023-11-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors","url":"https://clinicaltrials.gov/study/NCT06128551"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06128551"}